CoChat
Sign Up
Cited by 153Bone health and osteoporosis researchRheumatoid Arthritis Research and TherapiesBone Metabolism and Diseases

Bone loss in patients with rheumatoid arthritis: Results from a population‐based cohort of 366 patients followed up for two years

Haugeberg, Glenn, Ørstavik, Ragnhild E., Uhlig, Till, Falch, Jan A., Halse, Johan I., Kvien, Tore K.·2002·Arthritis & Rheumatism
DOI 10.1002/art.10408
Open this paper in CoChat — free account

Abstract

Objective: To evaluate the extent of and risk factors for bone loss in a population‐based cohort of patients with rheumatoid arthritis (RA) receiving conventional health care. Methods: In a longitudinal study, clinical data were collected and bone mineral density (BMD) measurements were performed at baseline and after 2 years. Dual‐energy x‐ray absorptiometry was used for hip and spine BMD measurements. At baseline, patients received advice about lifestyle adjustments and calcium and vitamin D supplementation; during the followup period they were treated with antirheumatic and bone‐sparing drugs, according to clinical judgment. Results: After a mean ± SD of 2.2 ± 0.2 years, 366 (298 women, 68 men) of the 488 patients who were examined at baseline were reexamined. At that time, 47.9% were current users of corticosteroids and 37.0% were using antiresorptive drugs (hormone replacement therapy, bisphosphonates, or calcitonin). The mean BMD reduction was −0.64% in the femoral neck, −0.77% in the total hip, and −0.29% in the spine at L2‐4. BMD was increased at all measurement sites in current users of antiresorptive drugs (0.16–1.64%) but was decreased in patients using calcium and vitamin D alone (−1.99% to −1.39%) and in patients not using any osteoporosis treatment (−1.20% to −0.43%). Current use of corticosteroids was independently associated with increased risk for BMD loss in the total hip (odds ratio [OR] 2.63, 95% confidence interval [95% CI] 1.38–5.00) and spine at L2‐4 (OR 2.70, 95% CI 1.30–5.63), whereas current use of antiresorptive drugs was associated with decreased risk for bone loss in the total hip (OR 0.43, 95% CI 0.20–0.89). Conclusion: Results of this population‐based, 2‐year followup study indicate that adequate management of patients with RA, addressing both the rheumatic disease and osteoporosis, protects against bone loss.

Integrity signals

Registry

Crossref · 10.1002/art.10408

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Haugeberg, G., Ørstavik, R. E., Uhlig, T., Falch, J. A., Halse, J. I., & Kvien, T. K.
Affiliations
  • Diakonhjemmet Hospital (NO)
  • Oslo University Hospital (NO)
ORCID
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2002-07
Volume
46
Issue
7
Pages
1720-1728
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
DOI
10.1002/art.10408
OpenAlex
W2030561091
Cited by
153
References
49
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 7 · 2020: 7 · 2019: 7 · 2018: 4 · 2017: 6 · 2016: 5 · 2015: 8 · 2014: 11 · 2013: 4 · 2012: 6
FWCI
9.85
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 10 d)
Locations
  • Arthritis & Rheumatism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • The Research Council of Norway
  • Lions Clubs International MD 104 Norway
  • Norwegian Rheumatism Association
  • Norwegian Women's Public Health Association
  • Trygve Gythfeldt and Wife Legacy
  • Grethe Harbitz Legacy
  • Marie and Else Mustad Legacy
  • Norwegian Osteoporosis Foundation
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
rheumatoid arthritis, bone loss, bone mineral density, osteoporosis, corticosteroids, antiresorptive agents, bisphosphonates, calcitonin, hormone replacement therapy, calcium and vitamin D supplementation, hip, spine, risk factors
MeSH terms
Adult, Aged, Anti-Inflammatory Agents, Arthritis, Rheumatoid, Bone Resorption, Calcitonin, Calcium, Diphosphonates, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Osteoporosis, Risk Factors, Vitamin D, Absorptiometry, Photon, Bone Density, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review